Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Anzueto A, Barjaktarevic I, Siler T, Rheault T, Bengtsson T, Rickard K
. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023; 208(4):406-416.
PMC: 10449067.
DOI: 10.1164/rccm.202306-0944OC.
View
2.
Agusti A, Fabbri L, Singh D, Vestbo J, Celli B, Franssen F
. Inhaled corticosteroids in COPD: friend or foe?. Eur Respir J. 2018; 52(6).
DOI: 10.1183/13993003.01219-2018.
View
3.
Yousuf A, McAuley H, Elneima O, Brightling C
. The different phenotypes of COPD. Br Med Bull. 2021; 137(1):82-97.
DOI: 10.1093/bmb/ldaa043.
View
4.
Vestbo J
. COPD: definition and phenotypes. Clin Chest Med. 2014; 35(1):1-6.
DOI: 10.1016/j.ccm.2013.10.010.
View
5.
Zuo H, Cattani-Cavalieri I, Musheshe N, Nikolaev V, Schmidt M
. Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther. 2019; 197:225-242.
DOI: 10.1016/j.pharmthera.2019.02.002.
View